Glycostem to participant the 63rd ASH Annual Meeting & Exposition virtually to present abstract online, about Clinical data of the first two acute myeloid leukemia patients enrolled in the phase I/IIa WiNK clinical trial.
Title: Allogeneic, CD34+, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease
Session Date/Time: 11th December 11, 2021 5:30 PM - 7:30 PM EST